GFWA
ABBV icon

Grey Fox Wealth Advisors’s AbbVie ABBV Stock Holding History

Grey Fox Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$611K Buy
2,427
+192
+9% +$41.3K 0.1% 94
2026
Q1 		$486K Sell
2,235
-360
-14% -$79.9K 0.09% 88
2025
Q4 		$593K Sell
2,595
-70
-3% -$15.9K 0.12% 78
2025
Q3 		$617K Sell
2,665
-28
-1% -$5.7K 0.13% 80
2025
Q2 		$500K Sell
2,693
-45
-2% -$8.36K 0.12% 82
2025
Q1 		$574K Buy
2,738
+31
+1% +$6.03K 0.15% 76
2024
Q4 		$481K Buy
2,707
+6
+0.2% +$1.1K 0.13% 86
2024
Q3 		$533K Sell
2,701
-109
-4% -$20.3K 0.15% 80
2024
Q2 		$482K Buy
2,810
+300
+12% +$49.7K 0.17% 75
2024
Q1 		$457K Buy
2,510
+6
+0.2% +$1.03K 0.17% 77
2023
Q4 		$388K Buy
2,504
+7
+0.3% +$1.02K 0.17% 75
2023
Q3 		$372K Buy
2,497
+77
+3% +$11.3K 0.19% 76
2023
Q2 		$326K Sell
2,420
-618
-20% -$90.6K 0.17% 77
2023
Q1 		$484K Buy
3,038
+34
+1% +$5.2K 0.29% 56
2022
Q4 		$485K Buy
+3,004
New +$461K 0.32% 52

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Grey Fox Wealth Advisors's ABBV Position: Q2 2026 in Review

Grey Fox Wealth Advisors increased its AbbVie (ABBV) stake by 8.6% in Q2 2026, buying an estimated $41.3K and bringing the position to 2,427 shares worth $611K. The position accounts for 0.1% of the portfolio, ranked #94.

Grey Fox Wealth Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $617K in Q3 2025. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Grey Fox Wealth Advisors held 2,427 shares of AbbVie worth $611K as of Q2 2026.
  • Grey Fox Wealth Advisors bought 192 AbbVie shares in Q2 2026, an estimated $41.3K.
  • AbbVie made up 0.1% of Grey Fox Wealth Advisors's portfolio in Q2 2026, its #94 holding.
  • Grey Fox Wealth Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • Grey Fox Wealth Advisors's AbbVie position peaked at $617K in Q3 2025.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Grey Fox Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.